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Radiotherapy outcomes are determined by complex interactions between physical and biological factors, reﬂecting both treatment
conditionsandunderlyinggenetics.Recentadvancesinradiotherapyandbiotechnologyprovidenewopportunitiesandchallenges
forpredictingradiation-inducedtoxicities,particularlyradiationpneumonitis(RP),inlungcancerpatients.Inthiswork,weutilize
datamining methods based on machine learning to build a predictive model of lung injury by retrospective analysis of treatment
planning archives. In addition, biomarkers for this model are extracted from a prospective clinical trial that collects blood serum
samples at multiple time points. We utilize a 3-way proteomics methodology to screen for diﬀerentially expressed proteins that are
related to RP. Our preliminary results demonstrate that kernel methods can capture nonlinear dose-volume interactions, but fail
to address missing biological factors. Our proteomics strategy yielded promising protein candidates, but their role in RP as well as
their interactions with dose-volume metrics remain to be determined.
Copyright © 2009 Sarah J. Spencer et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Lung cancer is one of the most lethal diseases among men
and women worldwide. Patients suﬀering from lung cancer
display a 5-year survival rate of only 15%, a value that
has held constant over the past 30 years. According to the
American Cancer Society (ACS) statistics, 215.020 new lung
cancer cases and 161.840 deaths due to lung cancer are
expected in the year 2008 alone [1]. This accounts for 29% of
all cancer deaths with 87% of these cases classiﬁed clinically
as nonsmall cell lung cancer (NSCLC). A large percentage of
lung cancer patients receive radiation therapy (radiotherapy)
as part of their standard of care and it is the main treatment
for inoperable patients at advanced stages of the disease.
Radiotherapy is a directed and localized treatment, but its
dose is limited by toxicities to surrounding normal tissues.
Thus, patients are at risk of experiencing tumor recurrence
if insuﬃcient dose was prescribed or conversely they are
susceptible to toxicities if exposed to excessive doses.
The last two decades have witnessed many techno-
logical advances in the development of three-dimensional
treatment planning systems and image-guided methods
to improve tumor localization while sparing surrounding
normal tissues [2, 3]. In parallel, there has been a tremen-
dous evolution in biotechnology providing high-throughput
genomics and proteomics information applicable within
cancer radiation biology. This has led to the birth of a
new ﬁeld in radiation oncology denoted as “radiogenomics”
or “radioproteomics” [4, 5]. These advances, if directed
properly, could pave the way for increasingly individualized
and patient-speciﬁc treatment planning decisions that con-
tinue to draw from estimates of tumor local control prob-
ability (TCP) or surrounding normal tissues complication
probability (NTCP) as illustrated in Figure 1.
Traditionally, tissue radioresponse has been modeled
using simplistic expressions of cell kill based on the linear-
quadratic (LQ) model developed in the 1940s [6]. The LQ2 Journal of Biomedicine and Biotechnology
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Figure 1: An S-shaped response curves representing tumor control
probability (TCP) and normal tissue complication probability
(NTCP) postradiotherapy as a function of treatment factors. The
probabilities could be constructed as a function of heterogeneous
variables (dose-volume metrics, biomarkers, and clinical factors).
Theradiotherapytreatmentobjectiveistomaximizethetherapeutic
index for each patient case.
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Figure 2: Radiotherapy treatment involves complex interaction of
physical, biological, and clinical factors. The successful datamining
approach should be able to resolve this interaction “puzzle” in the
observed treatment outcome (e.g., radiation-induced lung injury)
for each individual patient.
formalism describes repairable and nonrepairable radiation
damage of diﬀerent tissue types with a few estimated
radiation sensitivity parameters from cell culture assays [7].
Despite the historical value of LQ-based models, several
authors have recently cautioned against its limitations [8, 9].
It is understood that radiotherapy outcomes are determined
by complex interactions between physical treatment factors,
anatomical structures, and patient-related genetic variables
as depicted in Figure 2.
Ad i ﬀerent approach based on datamining of patient
information (clinical, physical, and biological records) has
been proposed to ameliorate these challenges and bridge
the gap between traditional radiobiological predictions from
in vitro assays and observed treatment outcomes in clin-
ical practice by understanding the underlying molecular
mechanisms [10–12]. The main idea of data-driven models
is to utilize datamining approaches and statistical model
building methods to integrate disparate predictive factors.
Suchmodelsmayimprovepredictivepower,buttheymustbe
simultaneously guarded for overﬁtting pitfalls using resam-
pling techniques, for instance. This approach is motivated by
the extraordinary increase in patient-speciﬁc biological and
clinical information from progress in genetics and imaging
technology. The main goal is to resolve the complicated
interactions by proper mixing of heterogeneous variables
(Figure 2). As a result, the treatment planning system could
be optimized to yield the best possible care for the patient as
illustrated in Figure 3.
Most data-driven models in the radiation oncology
literature could be categorized into two types of models:
(1) physical dose-volume models or (2) single-biomarkers
models. Dose-volume models are driven by the presence of
large treatment planning archives and the current clinical
practice of radiotherapy treatment. Current radiotherapy
protocols allow for the extraction of parameters that relate
irradiation dose to the treated volume fractions (tumors
or surrounding normal organs at risk) in dose-volume his-
tograms[13].Conversely,screeningfordiﬀerentblood/tissue
biomarkers to predict radiation response (TCP or NTCP)
is an emerging ﬁeld in radiation oncology with many
promising opportunities as well as new technical challenges
regarding data collection quality, the advancement of lab
techniques, and the development of statistical methodology
[14].
To illustrate and investigate the changing landscape of
radiation response modeling, our study addresses radiation
pneumonitis (RP), the major dose limiting toxicity in
thoracic irradiation. Clinically, RP is lung inﬂammation that
usually occurs within six months after therapy for a subset
of patients and can manifest as cough, dyspnea, fever, and/or
malaise which may require signiﬁcant supportive measures
including steroids and oxygen supplementation [15]. In its
worst form, RP can continue to progress and result in death.
According to the NCI Common Terminology Criteria for
Adverse Events (CTCAEs) v3.0, a clinical scoring system for
RP, the severity of pneumonitis is graded from 0 (minimal
symptoms) to 4 (most severe/life-threatening) or even 5
(death). A CTCAE-v3.0 grade ≥3 indicates clinical onset of
severe RP. Biologically, the ionizing radiation from treatment
can cause damage to the normal alveolar epithelium cells
(airways) of the lung resulting in release of a wetting agent
surfactant into the alveolar space and detachment of the
pneumocytes from their basement membrane. It is thought
that this process triggers a cascade of humoral cellular
and immune response events among alveolar epithelium,
ﬁbroblasts, lymphocytes, and macrophages leading to RP as
shown in Figure 4 [16].
We conjecture that a good predictive model for radiation
hypersensitivityshouldbeabletoproperlydescribetheinter-
actions between physical and biological processes resulting
from radiation exposure and adequately span the variableJournal of Biomedicine and Biotechnology 3
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Figure 3: The datamining understanding of these heterogeneous variables interactions could be fed back into the treatment planning system
to improve patient’s outcomes.
space shown in Figure 2. Working towards this standard,
we will present our utilization of supervised and unsuper-
vised machine learning approaches to interrogate radiation
oncology data and develop methodology for building better
predictive models of radiation therapy response. We start by
examining existing treatment planning archives and conduct
retrospective analysis of physical dose-volume models to
predict the onset of RP. We then describe our attempt to
ﬁllin the prediction gap in such physical models through
a prospective study that considers preexisting biological
variables, which may inﬂuence treatment response. Note
that the retrospective study has the advantage of large
sample size and hence higher power while the prospective
approach is focused towards improving current prediction
by incorporating missing information in past archives into
more comprehensive databases and performing evaluation
on new unseen data. In particular, we will present our
proteomic methodology to investigate predictive biomarkers
of RP that could eliminate informational gaps in our
r e t r o s p e c t i v ep h y s i c a lm o d e l .
The paper is organized as follows. In Section 2,w e
describe our retrospective analysis of dose-volume RP
predictors and our current prospective proteomic analysis.
In Section 3, we contrast our results using model-building
approaches based on logistic regression, support vector
machine, and a 3-way design for biomarker discovery in
proteomic analysis of RP. Methods for variable selections are
analyzed. Lastly, in Section 4 we discuss our current ﬁndings
and oﬀer some concluding remarks in Section 5.
2.MaterialsandMethods
2.1. Dataset Description. To demonstrate our methodol-
ogy, separate datasets were compiled using data from
two groups of patients all diagnosed with nonsmall cell
lung cancer (NSCLC) and treated with three-dimensional
conformal radiation therapy (3D-CRT) at our institution.
The ﬁrst dataset was collected retrospectively from the
clinical archives with median doses around 70Gy (the doses
were corrected to account for lung heterogeneity using the
tissue-air ratio method). In this set, 52 out of 219 patients
were diagnosed with postradiation late pneumonitis (RTOG
grade ≥3). The dataset included clinical and dosimetric
(dose-volume) variables. The clinical variables included
age, gender, ethnicity, date of treatment start, treatment
technique, treatment aim, chemotherapy, disease stage,
treatment duration, histological features, and so forth. The
dosimetric variables compiled for this retrospective dataset
were measured and calculated in reference to the extensive
dose-volume documentation in the radiation oncology liter-
ature. Typically, these metrics are extracted from the dose-
volume histogram (DVH) and include Vx (the percentage
volume that got x Gy), Dx (the minimum dose to the
hottest x% volume), mean dose, maximum and minimum
doses, generalized equivalent uniform, and so forth. In-
house software tools for data dearchiving, the analysis
software a Computational Environment for Radiotherapy
Research (CERR) [17], and the dose response explorer
system (DREES) [18] were used to extract the diﬀerent
metrics and analyze their association with RP.4 Journal of Biomedicine and Biotechnology
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Figure 4: A schematic diagram of the possible cellular and molecular events involved in pulmonary injury by radiation. Cellular interaction
among endothelial cells, alveolar epithelial cells, macrophages, lymphocytes, and ﬁbroblasts, through cytokine mediators of chemokines,
selectins, inﬂammatory cytokines, and ﬁbrotic cytokines are involved (from Chen et al., Seminars in Surgical Oncology, 2003).
TheseconddatasetwascollectedfromSeptember2007to
September 2008 for a prospective analysis. Nineteen patients
were involved in the study and underwent conventional
radiotherapy with mean doses close to 70Gy. Out of
nineteen patients, four were diagnosed with postradiation
late pneumonitis (RTOG grade ≥3). The data collected
for each patient included the same clinical and dosimetric
variables as the prospective study. In addition to this data,
ﬁve blood samples were drawn from each patient over
the course of treatment. These sample collections were
scheduled before radiotherapy (pretreatment), midtreat-
ment, immediately after radiotherapy (posttreatment), and
also at a three month and at six-month follow-up appoint-
ments.
This second dataset is gathered from an institutionally
approved prospective study for extracting biomarkers to
predict radiotherapy response in inoperable stage III NSCLC
patients who receive radiotherapy as part of their treatment.
For our preliminary proteomic screening, we selected two
lung cancer patients who were treated using fractionated
radiotherapy according to our institute clinical standards.
One case was designated as control and the other case
was for a patient who developed RP and designated as
disease. The control patient, despite radiation treatment
for advanced lung cancer, developed no adverse health
conditions throughout a follow-up period of 14 months. RP
typically occurs within the ﬁrst year posttreatment with a
mode of 6 months. The disease case selected for the study
died due to a severe RP episode one month after the end of
treatment. For both the control and disease cases, a serum
sample drawn before treatment as well as a sample drawn at
the last available follow-up was submitted for liquid chro-
matography mass spectrometry (LC-MS) analysis. A Seppro
15 × 13mm chromatography column (LC20) (GenWay
Biotech Inc., San Diego, Calif, USA) was used to deplete the
thawed samples of the 14 most abundant proteins in human
blood serum. The samples then underwent digestion by the
serine protease trypsin with a 10μg Bovine Serum Albumin
(BSA) external standard. Subsequent LC-MS allowed for the
separationandmassanalysisoftrypticpeptidesineachofthe
four samples. The most abundant peptides of each MS mass
scan were automatically sent to a second mass spectrometer
for fragmentation and sequence determination according to
a tandem MS (MS/MS) design.
2.2. Model Building Approach. In the context of data-driven
outcomes modeling, the observed treatment outcome (e.g.,
normal tissue complication probability (NTCP) or tumor
control probability (TCP)) is considered as the result of
functional mapping of multiple dosimetric, clinical, or
biological input variables [19]. Mathematically, this could be
expressed as f(x;w∗):X → Y,w h e r exi ∈ Rd are the input
explanatory variables (dose-volume metrics, patient disease
s p e c i ﬁ cp r o g n o s t i cf a c t o r s ,o rb i o l o g i c a lm a r k e r s )o fl e n g t h
d, yi ∈ Yare the corresponding observed treatment outcome
(TCP or NTCP), and w∗ includes the optimal parameters
of outcome model f(·) obtained by optimizing a certain
objective criteria. In our previous work [10, 19] ,al o g i t
transformation was used as follows:
f (xi) =
eg(xi)
1+eg(xi), i = 1,...,n,( 1 )Journal of Biomedicine and Biotechnology 5
where n is the number of cases (patients), xi is a vector of the
input variable values used to predict f(xi) for outcome yi of
the ith patient. The “x-axis” summation g(xi)i sg i v e nb y
g(xi) = βo +
d 
j=1
βjxij, i = 1,...,n, j = 1,...,d,( 2 )
where d is the number of model variables and the β’s are
the set of model coeﬃcients determined by maximizing
the probability that the data gave rise to the observations.
A major weakness in using this formulation, however, is
that the model capacity to learn is limited. In addition, (2)
requires the user feedback to determine whether interaction
terms or higher order terms should be added, making it a
trial and error process. A solution to ameliorate this problem
isoﬀeredbyapplyingmachinelearningmethodsasdiscussed
in the next section.
2.3. Kernel-Based Methods. Kernel-based methods and their
most prominent member, support vector machines (SVMs),
are universal constructive learning procedures based on the
statistical learning theory [20]. These methods have been
applied successfully in many diverse areas [21–25].
Statistical Learning. Learning is deﬁned in this context as
estimating dependencies from data [26]. There are two
common types of learning: supervised and unsupervised.
Supervised learning is used to estimate an unknown (input,
output) mapping from known (input, output) samples
(e.g., classiﬁcation or regression). In unsupervised learning,
only input samples are given to the learning system (e.g.,
clustering or dimensionality reduction). In this study, we
focus mainly on supervised learning, wherein the endpoints
of the treatments such as tumor control or toxicity grade
are provided by experienced oncologists following RTOG or
NCIcriteria.Nevertheless,wewilluseunsupervisedmethods
such as principle component analysis and multidimensional
scaling to aid visualization of multivariate data and guide the
selection of proper schemes for data analysis.
The main objective of supervised learning is to estimate
a parametric function f (x;w∗):X → Y by assistance
from a representative training set {(xi, yi)}
n
i=1. The two main
supervised learning tasks are classiﬁcation and regression.
The diﬀerence between classiﬁcation and regression is that
the output y in case of classiﬁcation belongs to a discrete, or
categorical,set y ∈{ 1,2,...,M}(e.g.,inbinaryclassiﬁcation
M = 2), whereas in regression y is a continuous variable.
In the example of classiﬁcation (i.e., discrimination between
patients who are at low risk versus patients who are at
high risk of radiation pneumonitis), the main function
of the kernel-based technique would be to separate these
two classes with “hyperplanes” that maximize the margin
(separation) between the classes in the nonlinear feature
space deﬁned by implicit kernel mapping. The objective
here is to minimize the bounds on the generalization error
of a model on unseen data before rather than minimizing
the mean-square error over the training dataset itself (data
ﬁtting). Consequently, the optimization problem could be
formulated as minimizing the following cost function:
L(w,ξ) =
1
2
wTw +C
n 
i=1
ξi,( 3 )
subject to the constraint:
yi

wTΦ(xi)+b

≥ 1 − ζi, i = 1,2,...,n,
ζi ≥ 0 ∀i,
(4)
where w is a weighting vector and Φ(·) is a nonlinear
mapping function. The ζi represents the tolerance error
allowed for each sample to be on the wrong side of the
margin (called hinge loss). Note that minimization of the
ﬁrst term in (3) increases the separation (margin) between
the two classes, whereas minimization of the second term
improves ﬁtting accuracy. The tradeoﬀ between complexity
(or margin separation) and ﬁtting error is controlled by the
regularization parameter C.
It stands to reason that such a nonlinear formulation
would suﬀer from the curse of dimensionality (i.e., the
dimensions of the problem become too large to solve)
[26, 27]. However, computational eﬃciency is achieved
from solving the dual optimization problem instead of (3).
The dual optimization problem is convex but positive-
semideﬁnite (global but not necessarily unique solution).
However, the complexity in this case is dependent only
on the number of samples and not on the dimensionality
of the feature space. Moreover, because of its rigorous
mathematical foundations, it overcomes the “black box”
stigma of other learning methods such as neural networks.
The prediction function in this case is characterized by only
a subset of the training data known as support vectors si:
f (x) =
ns 
i=1
αiyiK(si,x)+α0,( 5 )
where ns is the number of support vectors, αi are the
dualcoeﬃcientsdeterminedbyquadraticprogramming,and
K(·, ·) is the kernel function. Typical kernels include
Polynomials:K(x,x
 ) = (xTx
  +c)
q
Radialbasisfunction(RBF):K(x,x )=exp

−
1
2σ2
 x −x  2

,
(6)
where c is a constant, q is the order of the polynomial, and σ
is the width of the radial basis functions. Note that the kernel
in these cases acts as a similarity function between sample
points in the feature space. Moreover, kernels enjoy closure
properties, that is, one can create admissible composite
kernels by weighted addition and multiplication of ele-
mentary kernels. This ﬂexibility allows for the construction
of a neural network by using a combination of sigmoidal
kernels. Alternatively, one could choose a logistic regression
equivalent kernel by replacing the hinge loss with the
binomial deviance.6 Journal of Biomedicine and Biotechnology
2.4. Model Variable Selection. Multivariate analysis often
involves a large number of variables or features [28]. The
main features that characterize the observations are usually
unknown. To address this, dimensionality reduction or
subset selection aims to ﬁnd the “signiﬁcant” set of features.
Although an ideal method would marginalize redundant
variables, such variables usually complicate data exploration
without signiﬁcance. As a result, identifying the best subset
of features is a challenge, especially in the case of nonlinear
models. The objective remains to reduce the model com-
plexity, decrease the computational burden, and improve the
generalizability on unseen data.
In any given pattern recognition problem, there is a
large number, K, of possible modeling features that could
be extracted from the patients’ data, making it necessary
to select a ﬁnite set of features d that has the most
discriminating power for the problem. An optimal subset
would be determined by an exhaustive search, which would
yield

K
d

. Fortunately, there are other and more eﬃcient
alternatives [29]. The straightforward method is to make
an educated guess based on experience and domain knowl-
edge, then apply a feature transformation (e.g., principle
component analysis (PCA)) [29, 30]. It is also common
to apply sensitivity analysis by using an organized search
such as sequential forward selection, sequential backward
selection, or a combination of both [29]. Diﬀerent methods
for sensitivity analysis have been proposed in literature; one
such proposal is to monitor the increment in the training
error when a feature is replaced by its mean. The feature
is considered relevant if the increment is high. A recursive
elimination technique that is based on machine learning has
been also suggested [31]. In this case, the dataset is initialized
to contain the whole set, the predictor (e.g., SVM classiﬁer)
is trained on the data, the features are ranked according
to a certain criteria (e.g., w ), and iteration continues
by eliminating the lowest ranked feature. In our previous
work [10], we used model-order determination based on
information theory and resampling techniques to select the
signiﬁcant variables.
2.5. Evaluation and Validation Methods. To evaluate the
performanceofourclassiﬁers,weusedMatthew’scorrelation
coeﬃcient (MCC) [32] as a performance evaluation metric
for classiﬁcation. An MCC value of 1 would indicate perfect
classiﬁcation, a value of −1 would indicate anticlassiﬁcation,
and a value close to zero would indicate no correlation. The
value of this metric, however, is proportional to the area
under the receiver-operating characteristics (ROCs) curve.
For ranking evaluation, we used Spearman’s correlation,
whichprovidesarobustestimatoroftrend.Thisisadesirable
property, particularly when ranking the quality of treatment
plans for diﬀerent patients.
We used resampling methods (leave-one-out cross-
validation (LOO) and bootstrap) for model selection and
performance comparison purposes. These methods provide
statistically sound results when the available data set is
limited [33]. Application of these methods for radiotherapy
outcome modeling is reviewed in our previous work [10].
2.6. Visualization of Higher Dimensional Data. Prior to
applying a kernel-based method, it is informative to run
a screening test by visualizing the data distribution. This
requires projecting the data into a lower dimensional space.
Techniques such as principal component analysis (PCA)
and multidimensional scaling (MDS) allow visualization
of complex data in plots with reduced dimensions, often
two- or three-dimensional spaces [34]. In PCA analysis, the
principal components (PCs) of a data matrix X (with zero
mean) are given by
PC = UTX = ΣVT,( 7 )
where UΣVT is the singular value decomposition of X. This
is equivalent to transformation into a new coordinate system
such that the greatest variance by any projection of the
data would lie on the ﬁrst coordinate (ﬁrst PC), the second
greatest variance on the second coordinate (second PC), and
so on.
MDS provides a nonlinear mapping that approximates
local geometric relationships between points in high-
dimensional space on a low-dimensional space that can be
visualized. The objective function referred to here as the
stress could be written as
L

y1,y 2,..., yn

=

i<j

dij −δij
	2,( 8 )
where δij represents the target lower-dimensional distances
and dij represents higher dimensional distances of the points
with K features each. The optimization problem in (8)
is solved as a nonlinear least squares problem using the
standard Levenberg-Marquardt algorithm.
2.7. 3-Way Experimental Design for Predicting RP from
Proteomic Data. T h ed e s i g no fo u rp r o s p e c t i v es t u d yu t i -
lized tools oﬀered within Rosetta software extensively. Four
diﬀerent treatment groups were identiﬁed to the program:
(1) control pretreatment (control-pre); (2) control post-
treatment (control-post); (3) disease pretreatment (disease-
pre); (4) disease posttreatment (disease-post). For these four
sets of MS data (generated from four serum samples), we
used the default parameters of Rosetta Elucidator (Rosetta
Inpharmatics LLC, Seattle, Wash, USA) to convert raw
data into aligned, combined, and ratio data as described
brieﬂy below. Annotations from peptides with Ion Scores
>40 were applied to all corresponding features. Func-
tional analysis of the identiﬁed proteins was carried using
the MetaCore software (GeneGo Inc., St Joseph, Mich,
USA).
OverView of Mass Spectroscopy Analysis. The Rosetta Elu-
cidator uses raw mass spectroscopy (MS) data as an input
and applies multiple normalizations and transformations
in order to align, quantify, and compare features between
samples. The steps of this process calculate three diﬀerent
types of data from the raw spectral input: aligned data,
combined data, and ratio data. Aligned data have been
converted into peak regions, or features, with correspondingJournal of Biomedicine and Biotechnology 7
Raw
data
Time
alignment
Aligned
data
Feature
extraction
Forward
transform
Image
scaling
Specify
numerators
Isotope
grouping
Charge
grouping
Isotope
grouping
Charge
grouping
Combine
intensities
Combine
intensities
Combine
intensities
Combine
intensities
Combine
intensities
Combine
intensities
Inverse
transform
Inverse
transform
Inverse
transform
Build
ratio data
Build
ratio data
Build
ratio data
Ratio data
Combined
data
Figure 5: Diagram describing the general data processing steps Rosetta Elucidator use to calculate diﬀe r e n td a t at y p e so u to fr a w ,s p e c t r a l
input from a mass spectrometer (from Rosetta Inpharmatics LLC, Seattle, Wash, USA).
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Figure 6: A 2D depiction of the raw MS data from the control-
pre sample. The graph plots m/z versus elution time and displays
intensity at a given point with color.
intensity values that can be compared across samples.
Combined data are composed of features with intensity
values scaled by global mean intensities and transformed
to stabilize error variance across samples. Ratio data are
calculated through scaled intensity comparison between any
two given sets of aligned data. The process is summarized in
Figure 5 and described in the following.
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Figure 7: A representation of aligned data features generated by
Rosetta Elucidator from the control-pre mass spectrum. The m/z
measurement from the mass spectrometer is plotted against the
liquid chromatography elution time, with a scale of color depicting
the intensity (total ion current or TIC) measured at each point. The
Elucidator system deﬁnes features by mathematically identifying
local intensity peak regions against background noise.
Data Alignment. In its ﬁrst stages, the Elucidator program
transforms raw data into aligned data. Since peaks are not
initially deﬁned in the data, alignment starts at the level
of the spectrum. The raw data for each sample include
extremely precise mass to charge ratios (m/z ratios), times
of elution from the liquid chromatogram, and detected
intensity values for all ionized protein fragments. These8 Journal of Biomedicine and Biotechnology
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Figure 8: Visualization of the 58 variables related to RP by PCA. (a) Variation explanation versus principle component (PC) index. This
represents the variance of the data model about the mean prognostic input factor values. (b) Data projection into the ﬁrst two components
space. Note the high overlap in projection space, which suggests nonlinear kernel modeling to achieve better predictive power.
values are converted into a pixelated image with an m/z
axis, an elution time axis, and corresponding intensity
values visualized with pixel color (Figure 6). From these raw
MS images, a master image is chosen and all remaining
raw images are aligned to that common spectrum. The
main purpose of initial spectral alignment is to correct for
variations in elution time that occur between MS runs.
Shifting a spectrum in time to match a master image allows
for meaningful comparison between corresponding peaks
in diﬀerent samples. Once this time-alignment has been
executed, the noise and background of each image are
removed to generate aligned data that can be viewed in the
system.
Feature Extraction. To extract meaningful peak regions, or
features, from aligned data, a merged image is created from
all the aligned images of the samples. To accomplish this,
intensity values are averaged within treatment groups at
each m/z and charge point. The resulting averaged treatment
images are then averaged again across all treatments to
generate a global merged image. Features can then be
deﬁned by overlaying ellipses or other two-dimensional
shapes, called masks, to capture appropriate peak regions.
The result across an experiment is a set of unique features
with intensities measured by total ion current (TIC). Each
individualfeaturerepresentsasingleisotopicmasspeakfrom
one of the charge states of a single peptide in a sample.
Following feature extraction, the features can be grouped by
isotope and the resulting isotope groups can be grouped by
charge in order to capture all the features corresponding to
a single peptide. An example of aligned data with extracted
features is shown in Figure 7.
Combined Data. Despite this extensive process, aligned
data generated by the Rosetta Elucidator system is still
not the most appropriate for the comparative questions
we are addressing. Aligned data generated from multiple
samples does not correct for certain experimental errors and
variations that occur between runs. In order to generate
the most meaningful data for comparison across samples,
Rosetta Elucidator converts aligned data into combined data.
The ﬁrst step in this transformation is a form of intensity
scaling that uses the mean intensity (or brightness) of a
sample, possibly the mean average brightness of samples in
a treatment group, and the mean average brightness across
an entire experiment. The mean brightness of a sample
is calculated by excluding any missing values and then
averaging the lowest 90% of feature intensity values. Each
intensity value is normalized by the mean intensity of its
treatment condition and the global mean intensity across the
experiment. This ensures that samples and treatments share
a common mean intensity, further facilitating comparisons
at the level of features, isotope groups, or charge groups.
Following intensity scaling, the Elucidator system applies
an error model-based transformation to stabilize the noise
variance over the range of intensities in use. The transform
function, shown below, converts the noise variance across all
samples to a constant value:

 x =
ln

b2 +2 a2 ·x +2
√
c2 +b2 ·x +a2 ·x2

a
+d,( 9 )
where the a and b terms are related to the type of MS
technology used. The a term is related to the fraction
error of the instrument and the b term is related to the
Poisson error of the instrument. In our experiment, we
used a Linear Trap Quadrupole Orbitrab (LTQ-ORBI) mass
spectrometer, which has a fraction error of 0.05 and aJournal of Biomedicine and Biotechnology 9
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Figure 9: RP with a premodeling variable selection using (a), (b) the recursive feature elimination (RFE) method. Variables were chosen
fromapoolof58dosimetric,positional,andclinicalvariables.Thetop23variablesselectedbySVM-RFEareshownafterapplyingapruning
step to correct for multicollinearity (RS = 0.75)(RS = 0.75). The top 6 variables (by applying a cutoﬀ of 5% weighting score) were used
for modeling pneumonitis. (b) An SVM-RBF classiﬁer was tested on LOO data. (c), (d) Multimetric logistic regression approach. (c) The
frequency of selected models order of 3 using our two-step resampling methods. The best-selected model consisted of three parameters
(D35, COM-SI, and maximum dose). (d) The results of applying the SVM methodology with RBF kernels using these selected variables on
LOO testing data. Note the improved performance in this case compared to RFE variable selection.
Poisson error of 15000. The c term depends upon each
feature’s background value, which is an error model output
for aligned data that calculates the background intensity
surrounding the feature (ideally zero). An average of the
background value is calculated over all features i and all
treatments j in the experiment. The term d is related through
a logarithm transform to a, b,a n dc. Following this forward
transform, the transformed intensity values are averaged
across all samples in the experiment to generate a separate
combined intensity value. This combined intensity value is
set apart from the individual sample intensity values and
is calculated for later comparative and testing purposes.
To generate the ﬁnal combined data set, all intensities
(including the combined intensity) must undergo an inverse
transformation.
Ratio Data. A ﬁnal type of data, called ratio data, is
calculatedfromtwo input sets ofaligned data,one markedas
a numerator and the other marked as a denominator. Ratio
data is especially informative for our experiment because
it provides a way to analyze relative intensity changes that
occur across the same feature in diﬀerent treatment groups
as discussed below.
Feature Annotation. With aligned data, combined data, and
ratio data calculated automatically as part of our exper-
imental design within Rosetta, we proceeded to annotate
the sample features with the initial MS/MS peptide and
protein identiﬁcations. All peptides with an Ion Score greater
than 40, as calculated in Mascot search engine for peptide10 Journal of Biomedicine and Biotechnology
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Figure 10: Categorization of upregulated and downregulated features for the ratio data as a function of average intensity for (a) control-post
to control-pre, (b) Disease-post to disease-pre, and (c) control-pre to disease-pre.
identiﬁcation (Matrix Science Ltd., Boston, Mass, USA)
were associated with their corresponding feature in Rosetta
Elucidator.
3. ExperimentalResults
3.1. Dose-Volume RP Model
DataExploration. InFigure 8,wepresentPCAanalysisofRP ,
with a pool of 58 variables. This pool included clinical vari-
ables (age, gender, race, chemo, stage, histology, treatment,
etc.),dosimetricvariables,suchasVx (volumegettingatleast
x Gy), Dx (minimum dose to the hottest x%v o l u m e ) ,a n d
the relative location of the tumor within the lung. Notice
that more than 93% of the variations in the input data
were explained by the ﬁrst two components (Figure 8(a)).
Additionally, the overlap between patients with and without
radiation pneumonitis is very high (Figure 8(b)), suggesting
that there is no linear classiﬁer that can adequately separate
these two classes.
Kernel-Based Modeling. We ﬁrst explored the eﬀect of vari-
able selection over the entire variable pool on the prediction
of pneumonitis in the lung using support vector machine
with a radial basis function kernel (SVM-RBF) as a classiﬁer.
In Figure 9(a), we show the top 30 selected variables using a
recursive-feature-elimination SVM method, which was pre-
viouslyshowntobeanexcellentmethodforgeneselectionin
microarraystudies[31].Weusedvariablepruningtoaccount
for multicolinearity of correlated variables in this case. In
Figure 9(b), we show the resulting SVM-RBF classiﬁer using
the top six variables (using a cutoﬀ of 5% weighting score).
ThebestMCCobtainedwas0.22.InFigure 9(c),weshowthe
results of variable selection using our previous multimetric
approach based on model order selection and resampling
with logistic regression [10, 19]. The model order was
determined to be 3 with variables of D35, max dose, and
COM-SI (center-of-mass of tumor location in the superior
inferior direction) [35]. Figure 9(d) shows the evaluation
results of applying the SVM methodology with RBF kernels
using these selected variables. The resulting correlation
(MCC = 0.34) on LOO testing data signiﬁcantly improved
our previously achieved multimetric logistic regression by
46%.Thebasicinterpretationofthisimprovementisthatthe
SVM automatically identiﬁed and accounted for interactions
between the model variables. Despite the improvement, the
model still does not achieve correlations levels that could
be applied with high conﬁdence in clinical practice. This is
possiblybecausethemodelisunabletoaccountforbiological
eﬀects adequately, which we might need to incorporate as
analyzed next.
3.2. Proteomic Identiﬁcation of RP. Using the 3-way method-
ology described in Section 2.7, we identiﬁed a group of
featuresassociatedwithRPbyoverlayingmultiplesubgroups
ofratiodataasfollows.First,weorganizedsubgroupsofratio
data that displayed signiﬁcant intensity changes between
any two samples of interest. Signiﬁcance was determined
based on the P-value of each feature in a given set of ratio
data. A P-value less than .05 was used as a cutoﬀ. In this
step, 11979 unique features were identiﬁed after spectral
alignment across the four samples. Of these 458 features
directly matched, a peptide with an Ion Score >40 and 1289
features were annotated when direct peptide matches (with
Ion Scores >40) were applied to all features in the same
isotope group. Signiﬁcant features could be further divided
into upregulated and downregulated categories based on the
sign of the fold change as shown in Figure 10.
Secondly, features that signiﬁcantly changed intensity
between control-pre and control-post were overlaid with
signiﬁcant features that changed between disease-pre and
disease-post. Shared features between these two datasets
indicated candidate peptides that changed expression due to
radiation. Alternatively, features unique to the disease-postJournal of Biomedicine and Biotechnology 11
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Figure 11: Diagram depicting the shared features between diﬀerent
sets of ratio data. The features in an individual set are those that
displayedasigniﬁcantchangeinintensitybetweenthetwomembers
of the ratio. (a) All four samples, (b) the three ratios used to extract
the RP candidates from the overlaid: control-pre to control-post,
disease-pre to disease-post, and control-pre to disease-pre. Eleven
features uniquely associated to a hypersensitive reaction as well as
diﬀerential between patients before treatment.
versus disease-pre signiﬁcant dataset were considered associ-
ated with a deleterious, hypersensitive reaction to radiation
therapy, RP in our case. Using this hypersensitive dataset, we
then overlaid the signiﬁcant features from control-pre versus
disease-pre. The features shared between these datasets are
not only associated with RP, but also can be detected (due
to diﬀerentialconcentrations)beforetreatmentinitiates.The
results of these comparisons are summarized in the Venn
diagrams of Figure 11.
As noted from Figure 11(b), 41 features signiﬁcantly
changed after treatment in both patients. This can be
attributed to regular radiation response. In addition, there
were 489 signiﬁcant features that were uniquely associated
with the control case and 38 that were uniquely associated
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Figure 12: Visualization of the candidate 11 features for RP (a)
PCA and (b) MDS. Note the separation between control-pre and
disease-preanddisease-postanddisease-preasanticipatedfromthe
experimental design strategy we followed to extract these features.
with the disease case. Eleven features were uniquely asso-
ciated with a hypersensitive reaction as well as diﬀerential
expression between patients before treatment, which rep-
resent our RP candidates. The relationship between these
features and the original samples is represented in the
PCA and MDS analyses of Figure 12. It is noticed that the
separation between control-pre and disease-pre and disease-
post and disease-pre is as anticipated from the experimental
design strategy we followed to extract these features.
These 11 features were annotated as described in
Section 2.7 and four proteins were identiﬁed as potential12 Journal of Biomedicine and Biotechnology
biomarkers for RP. All the identiﬁed proteins were downreg-
ulated postradiotherapy treatment and were known to play
roles in inﬂammation responses. Two of these protein fam-
ilies were related to tissue remodeling, cognitive disorders,
and ﬁbrosis; one protein was part of the angiotensin-renin
system, and the last protein seems to play a role in cytokine
expression (interleukins and tumor necrosis factor).
4. Discussion
Modelingofradiotherapyoutcomesconstitutesachallenging
problem due to the complex interaction between physical
and biological factors. Better understanding of these rela-
tionships and the ability to develop predictive models of
patients’ treatment outcomes would lead to personalized
treatment regimens. The tremendous increase in patient-
speciﬁc clinical and biological information in conjunction
with developing proper datamining methods and bioinfor-
matics tools could potentially revolutionize the century old
concepts of radiobiology and potentially improve the quality
of care for radiation oncology patients.
In this work, we presented our methodology for making
use of currently existing treatment planning archives to
develop dose-volume models. We have demonstrated that
supervised machine learning methods based on nonlinear
kernels could be used to improve prediction of RP by a
factor of 46% compared to traditional logistic regression
methods. Potential beneﬁts of these methods could be
assessed based on PCA analysis of this data, where nonlinear
kernels could be applied to resolve overlapping classes by
mapping to higher-dimensional space [36]. We have applied
resampling methods based on LOO to assess generalizabilty
to unseen data and avoid overﬁtting pitfalls. Despite the gain
in performancewe attained from kernel methods, our results
showthatthebestpredictivemodelofRPhasanMCCof0.34
on LOO suggesting that our current variable space of clinical
and physical dosimetric variables may not be adequate to
describe the observed outcomes. This is despite the inclusion
of high-order interaction terms using the SVM machinery.
Therefore, we are currently exploring the inclusion of bio-
logical variables from peripheral blood draws to improve the
prediction power of our RP model. Toward this goal, we have
proposed a prospective study that builds upon our earlier
retrospective analysis to delineate dose-volume eﬀects in the
onset of RP and include “missing” biological variables from
minimally invasive clinical procedures inoperable NSCLC
patients.
We have conducted a proteomic analysis of blood serum
samples. Speciﬁcally, we have proposed a 3-way design
strategy in order to distinguish between patient’s variations,
confounding radiation eﬀects, and hypersensitivity predic-
tors using intensity ratio changes. To test the validity of our
design, PCA and MDS plots were used to measure separation
between the samples in the estimated feature space. Our
proteomicanalysiswasbasedondatafromonlytwosamples,
but the results still provided promising candidates to validate
with biochemical assays in a larger cohort. The entire study
size of nineteen patients is an arguably small sample size
as well, but according to our current protocol the number
of patients in this study will increase every year, as new
patients are recruited, with a ﬁnal goal of 100–120 patients
participating. Ongoing generation and validation of candi-
date proteins through additional mass spectrometry runs
and extensive biochemical assaysshould provide increasingly
interesting and accurate candidate proteins. Our feature
selection strategy for candidate proteins is simplistic at this
point, but we plan to make eﬀective use of new emerging
methodologies in statistical analysis of such data [37–40].
However, further investigation of datamining approaches to
extract proper features and identify corresponding proteins
with higher conﬁdence from limited datasets is still required.
In our future work, we plan to further validate the
derived proteins by examining their functional role by
querying protein databases and measure their expression
using Enzyme-Linked ImmunoSorbent Assay (ELISA). If
successful, this data would be mixed with the developed
dose-volume model using SVM-RBF and we will test the
overall prediction on prospective data. Thus, we would be
able to beneﬁt from both retrospective and prospective data
in our model building strategy.
5. Conclusions
We have demonstrated machine-learning application and a
proteomics design strategy for building a predictive model
of RP. The machine learning methods eﬃciently and eﬀec-
tively handle high-dimensional space of potentially critical
features. We have applied this model successfully to inter-
rogate dose-volume metrics. Our proteomics strategy seems
to identify relevant biomarkers to inﬂammation response.
Furthermore, we are currently investigating incorporation of
these biomarkers into our existing dose-volume model of RP
to improve its prediction power and potentially demonstrate
its feasibility for individualization of radiotherapy of NSCLC
patients.
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